GSK Annual Report 2002

More documents

Recommendations

Info

144 GlaxoSmithKline Financial record Pharmaceutical sales – total Group Q4 2002 Q3 2002 Q2 2002 Q1 2002 £m CER % £m CER % £m CER % £m CER % CNS 1,227 15 1,124 21 1,166 21 994 10 Depression 813 18 740 29 761 30 623 10 Seroxat/Paxil 566 10 499 20 552 29 438 1 Wellbutrin 247 42 241 52 209 34 185 41 Migraine 233 6 217 4 230 6 208 19 Imigran/Imitrex 211 8 197 5 206 6 184 19 Naramig/Amerge 22 (7) 20 (10) 24 7 24 17 Lamictal 121 25 107 25 110 24 100 35 Requip 25 64 21 (5) 24 25 19 14 Zyban 22 (7) 23 4 25 (28) 29 (37) Respiratory 1,066 15 922 11 1,032 15 967 25 Seretide/Advair, Flixotide/Flovent, Serevent 806 27 686 17 746 22 699 37 Seretide/Advair 460 50 392 70 416 >100 363 >100 Flixotide/Flovent 211 7 178 (15) 194 (22) 200 (14) Serevent 135 1 116 (21) 136 (19) 136 (25) Flixonase/Flonase 122 – 125 16 150 17 137 9 Ventolin 73 (8) 58 (10) 66 (17) 68 (3) Becotide 33 (21) 30 (20) 34 (13) 33 (19) Anti-virals 621 9 558 11 570 12 550 17 HIV 396 13 357 12 362 9 350 18 Combivir 155 4 141 (1) 148 (1) 144 – Trizivir 90 46 77 75 79 >100 69 >100 Epivir 80 7 71 1 72 (6) 72 1 Retrovir 13 (6) 10 (28) 13 – 14 14 Ziagen 47 16 47 26 39 (8) 40 6 Agenerase 11 (6) 11 (9) 11 (12) 11 (3) Herpes 175 1 156 7 166 6 156 7 Valtrex 121 24 103 22 105 31 96 27 Zovirax 54 (28) 53 (14) 61 (20) 60 (14) Zeffix 33 29 31 19 29 10 30 37 Anti-bacterials 573 (21) 434 (15) 559 (3) 644 (9) Augmentin 293 (31) 197 (24) 313 10 388 (4) Zinnat/Ceftin 67 (37) 50 (30) 57 (49) 69 (37) Fortum 53 (7) 46 (4) 51 2 51 3 Amoxil 43 13 30 (3) 30 (5) 33 (24) Metabolic and gastro-intestinal 402 32 289 (23) 385 (5) 353 5 Avandia 236 >100 155 (26) 222 4 196 28 Zantac 98 (27) 81 (24) 101 (21) 102 (13) Vaccines 278 12 297 26 261 8 244 18 Hepatitis 123 10 121 16 121 11 118 10 Infanrix 54 (12) 67 27 69 (1) 64 24 Oncology and emesis 268 35 231 13 247 11 231 26 Zofran 200 36 171 19 178 13 159 20 Hycamtin 23 60 19 (26) 27 5 25 16 Cardiovascular 172 2 169 26 169 16 145 17 Coreg 76 (3) 93 64 77 36 60 22 Arthritis (Relafen) 4 (78) 5 (83) 7 (86) 7 (86) Other 188 (20) 193 (6) 217 (3) 226 10 Total pharmaceutical sales 4,799 7 4,222 6 4,613 9 4,361 10
Financial record GlaxoSmithKline 145 Pharmaceutical sales – USA Q4 2002 Q3 2002 Q2 2002 Q1 2002 £m CER % £m CER % £m CER % £m CER % CNS 900 19 834 27 859 27 712 13 Depression 628 21 583 36 590 37 474 10 Seroxat/Paxil 386 10 347 27 387 39 293 (3) Wellbutrin 242 42 236 53 203 35 181 41 Migraine 176 12 164 6 175 7 155 20 Imigran/Imitrex 163 13 153 8 159 7 141 21 Naramig/Amerge 13 (5) 11 (16) 16 12 14 20 Lamictal 67 39 61 41 64 44 55 55 Requip 14 >100 11 (10) 13 43 9 15 Zyban 11 (4) 12 (3) 11 (17) 13 (15) Respiratory 529 28 475 19 531 24 488 46 Seretide/Advair, Flixotide/Flovent, Serevent 425 43 366 24 394 29 372 60 Seretide/Advair 251 71 210 >100 224 >100 191 >100 Flixotide/Flovent 101 25 90 (20) 95 (30) 101 (18) Serevent 73 5 66 (27) 75 (25) 80 (26) Flixonase/Flonase 92 1 103 19 119 24 99 16 Ventolin 3 (62) (2) – 1 (91) 6 (21) Becotide – – – – – – – – Anti-virals 326 12 299 16 294 19 294 28 HIV 227 8 215 14 210 8 205 21 Combivir 88 (1) 82 (2) 84 (3) 84 (1) Trizivir 53 29 50 69 52 >100 45 >100 Epivir 45 8 41 8 39 (4) 39 11 Retrovir 6 (7) 6 (5) 5 (9) 6 20 Ziagen 27 13 28 24 22 (14) 24 8 Agenerase 8 (4) 8 (14) 8 (25) 7 (18) Herpes 86 18 72 21 74 24 77 46 Valtrex 79 34 65 29 68 34 63 44 Zovirax 7 (48) 7 (22) 6 (28) 14 56 Zeffix 3 53 3 72 3 57 3 >100 Anti-bacterials 232 (34) 155 (34) 262 (3) 326 (17) Augmentin 163 (41) 88 (40) 196 18 257 (7) Zinnat/Ceftin 9 (77) 5 (79) 7 (87) 13 (77) Fortum 10 6 9 (23) 9 3 9 (3) Amoxil 9 >100 8 4 8 63 7 (56) Metabolic and gastro-intestinal 229 >100 148 (30) 215 (2) 192 19 Avandia 198 >100 130 (32) 193 (1) 167 21 Zantac 23 (29) 17 (15) 21 (14) 25 (1) Vaccines 65 1 73 16 70 14 82 35 Hepatitis 55 15 53 23 48 9 55 24 Infanrix 10 (36) 19 (4) 23 40 27 72 Oncology and emesis 208 49 173 14 185 13 174 33 Zofran 154 51 125 22 130 15 116 24 Hycamtin 15 >100 12 (36) 19 4 17 24 Cardiovascular 112 (1) 115 30 110 25 93 17 Coreg 73 (4) 90 66 75 37 57 21 Arthritis (Relafen) 1 (91) 2 (92) 2 (96) 3 (93) Other (10) >(100) 5 80 23 (15) 11 >100 Total pharmaceutical sales 2,592 14 2,279 9 2,551 15 2,375 15
Page 1 and 2:
Do more, feel better, live longer T
Page 3 and 4:
The Annual Report was approved by t
Page 5 and 6:
Joint statement by the Chairman and
Page 7 and 8:
04 GlaxoSmithKline Joint statement
Page 9 and 10:
Products - Pharmaceuticals Descript
Page 11 and 12:
Additionally, GlaxoSmithKline marke
Page 13 and 14:
Competition - Consumer Healthcare T
Page 15 and 16:
Operating activities Marketing and
Page 17 and 18:
Description of business GlaxoSmithK
Page 19 and 20:
Description of business GlaxoSmithK
Page 21 and 22:
Product approvals Country/Region Pr
Page 23 and 24:
As part of GlaxoSmithKline’s majo
Page 25 and 26:
Operating resources Intellectual pr
Page 27 and 28:
Compensation philosophy and program
Page 29 and 30:
Access to healthcare in the develop
Page 31 and 32:
GlaxoSmithKline gave unrestricted g
Page 33 and 34:
Corporate governance This section d
Page 35 and 36:
Corporate Executive Team (CET) JP G
Page 37 and 38:
The Annual General Meeting takes pl
Page 39 and 40:
Research and development Safety of
Page 41 and 42:
Remuneration report GlaxoSmithKline
Page 43 and 44:
The majority of the competitor pane
Page 45 and 46:
Performance graph 100 90 80 70 60 N
Page 47 and 48:
Non-Executive Directors Non-Executi
Page 49 and 50:
Non-Executive Directors’ share ar
Page 51 and 52:
Incentive plans Remuneration report
Page 53 and 54:
Operating and financial review and
Page 55 and 56:
2002 Year World economy The world
Page 57 and 58:
Pharmaceutical sales by therapeutic
Page 59 and 60:
Consumer Healthcare sales 2002 2001
Page 61 and 62:
Earnings 2001 2002 (restated) CER%
Page 63 and 64:
Contractual obligations and commitm
Page 65 and 66:
Funding, maturity and counterparty
Page 67 and 68:
Stricter regulatory controls also h
Page 69 and 70:
Operating and financial review and
Page 71 and 72:
Latin America reported eight per ce
Page 73 and 74:
Selected financial data UK/US GAAP
Page 75 and 76:
Financial statements GlaxoSmithKlin
Page 77 and 78:
Independent Auditors’ report to t
Page 79 and 80:
Consolidated statement of profit an
Page 81 and 82:
Consolidated statement of cash flow
Page 83 and 84:
Company balance sheet at 31st Decem
Page 85 and 86:
2 Accounting policies Consolidation
Page 87 and 88:
2 Accounting policies continued Sto
Page 89 and 90:
6 Segment information continued Not
Page 91 and 92:
7 Merger items, restructuring costs
Page 93 and 94:
Notes to the financial statements G
Page 95 and 96: 13 Earnings per share Notes to the
Page 97 and 98: Notes to the financial statements G
Page 99 and 100: 19 Equity investments Notes to the
Page 105 and 106: 30 Legal proceedings The Group is i
Page 107 and 108: 30 Legal proceedings continued In F
Page 109 and 110: 30 Legal proceedings continued In 2
Page 111 and 112: 31 Acquisitions and disposals conti
Page 113 and 114: 32 Financial instruments and relate
Page 115 and 116: 32 Financial instruments and relate
Page 117 and 118: 33 Employee costs continued Notes t
Page 119 and 120: 33 Employee costs continued Notes t
Page 121 and 122: 34 Employee share schemes continued
Page 123 and 124: 34 Employee share schemes continued
Page 125 and 126: 37 Reconciliation to US accounting
Page 141 and 142: 38 Principal Group companies Notes
Page 143 and 144: 38 Principal Group companies contin
Page 145: Financial record GlaxoSmithKline 14
Page 149 and 150: Financial record GlaxoSmithKline 14
Page 151 and 152: Financial record GlaxoSmithKline 14
Page 153 and 154: Investor information GlaxoSmithKlin
Page 155 and 156: Shareholder information Ordinary sh
Page 157 and 158: Share capital GlaxoSmithKline 155 A
Page 159 and 160: Cross reference to Form 20-F GlaxoS
Page 161 and 162: Index A Access to healthcare 27 Acc
Page 163: Contact details INTERNET Informatio
show all

GSK Annual Report 2002

Create successful ePaper yourself

Delete template?

Save as template?